Physician profile
Laura Harper
NPI 1760805444
$1,418.31
in general payments reported to CMS, 2019-2025
16 companies · $776 in 2025
The $776 reported for 2025 was more than what 87% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.51 · 2022: $459 · 2023: $161 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $396.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Gilead Sciences, INC. | $201.35 | 2025 | Yeztugo |
| Pfizer INC. | $146.51 | 2022-2025 | |
| Atricure, INC. | $126.27 | 2022 | |
| Eisai INC. | $124.99 | 2023 | |
| Edwards Lifesciences Corporation | $106.10 | 2022 | |
| Merck Sharp & Dohme LLC | $62.49 | 2025 | Pifeltro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.91 | 2022 | |
| Viiv Healthcare Company | $45.79 | 2025 | Apretude, Rukobia |
| Glaxosmithkline, LLC. | $41.70 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi Pasteur INC. | $26.36 | 2025 | |
| Lilly USA, LLC | $22.69 | 2025 | Mounjaro, Zepbound |
| Braeburn INC. | $20.46 | 2025 | Brixadi |
| Medtronic, INC. | $17.08 | 2023 | Linq II |
| Bayer Healthcare Pharmaceuticals INC. | $14.34 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $13.64 | 2025 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.